Tulane Research and Innovation for Arrhythmia Discoveries-TRIAD Center, Tulane University School of Medicine, New Orleans, LA, USA.
Clinic for Electrophysiology, Herz- Und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany.
J Interv Card Electrophysiol. 2024 Nov;67(8):1843-1850. doi: 10.1007/s10840-024-01831-w. Epub 2024 Jun 7.
Catheter ablation is recognized as an effective treatment for atrial fibrillation (AF). Despite its effectiveness, significant sex-specific differences have been observed, which influence the outcomes of the procedure. This study explores these differences in a cohort of patients with persistent AF. We aim to assess sex differences in baseline characteristics, symptoms, quality of life, imaging findings, and response to catheter ablation in patients with persistent AF.
This post hoc analysis of the DECAAF II trial evaluated 815 patients (161 females, 646 males). Between July 2016 and January 2020, participants were enrolled and randomly assigned to receive either personalized ablation targeting left atrial (LA) fibrosis using DE-MRI in conjunction with pulmonary vein isolation (PVI) or PVI alone. In this analysis, we aimed to compare female and male patients in the full cohort in terms of demographics, risk factors, medications, and outcomes such as AF recurrence, AF burden, LA volume reduction assessed by LGE-MRI before and 3 months after ablation, quality of life assessed by the SF-36 score, and safety outcomes. Statistical methods included t-tests, chi-square, and multivariable Cox regression.
Females were generally older with more comorbidities and experienced higher rates of arrhythmia recurrence post-ablation (53.3% vs. 40.2%, p < 0.01). Females also showed a higher AF burden (21% vs. 16%, p < 0.01) and a smaller reduction in left atrial volume indexed to body surface area post-ablation compared to male patients (8.36 (9.94) vs 11.35 (13.12), p-value 0.019). Quality of life scores were significantly worse in females both pre- and post-ablation (54 vs. 66 pre-ablation; 69 vs. 81 post-ablation, both p < 0.01), despite similar improvements across sexes. Safety outcomes and procedural parameters were similar between male and female patients.
The study highlights significant differences in the outcomes of catheter ablation of persistent AF between sexes, with female patients showing worse quality of life, higher recurrence of AF and AF burden after ablation, and worse LA remodeling.
导管消融术已被公认为治疗心房颤动(AF)的有效方法。尽管其效果显著,但在该程序的结果方面,存在显著的性别特异性差异。本研究旨在探讨持续性 AF 患者队列中的这些差异。我们旨在评估持续性 AF 患者的基线特征、症状、生活质量、影像学发现以及对导管消融反应的性别差异。
本研究是 DECAAF II 试验的事后分析,共纳入 815 例患者(女性 161 例,男性 646 例)。在 2016 年 7 月至 2020 年 1 月期间,招募参与者并随机分配接受个性化消融治疗,消融靶点为左心房(LA)纤维化,采用 DE-MRI 结合肺静脉隔离(PVI)或仅 PVI。在这项分析中,我们旨在比较全队列中女性和男性患者在人口统计学、风险因素、药物治疗以及 AF 复发、AF 负荷、消融前和消融后 3 个月通过 LGE-MRI 评估的 LA 容积减少、生活质量通过 SF-36 评分评估以及安全性结果等方面的差异。统计方法包括 t 检验、卡方检验和多变量 Cox 回归。
女性通常年龄较大,合并症较多,消融后心律失常复发率较高(53.3%比 40.2%,p<0.01)。与男性患者相比,女性患者的 AF 负荷更高(21%比 16%,p<0.01),消融后左心房容积指数减少更少(8.36(9.94)比 11.35(13.12),p 值为 0.019)。尽管女性的生活质量评分在消融前后均显著降低(消融前 54 分比 66 分;消融后 69 分比 81 分,均 p<0.01),但仍存在差异。男性和女性患者的安全性结果和手术参数相似。
该研究强调了导管消融治疗持续性 AF 结果在性别之间存在显著差异,女性患者的生活质量更差,消融后 AF 复发和 AF 负荷更高,左心房重构更差。